NASDAQ:EVOK Evoke Pharma (EVOK) Stock Forecast, Price & News $1.08 0.00 (0.00%) (As of 01:29 PM ET) Add Compare Share Share Today's Range$0.99▼$1.1050-Day Range$0.96▼$1.7352-Week Range$0.92▼$5.96Volume1,196 shsAverage Volume26,041 shsMarket Capitalization$3.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Evoke Pharma (NASDAQ:EVOK) StockEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More EVOK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVOK Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Shares Cross Below Two Hundred Day Moving Average of $1.77September 23, 2023 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.comSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 14, 2023 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTISeptember 14, 2023 | finance.yahoo.comEvoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®August 15, 2023 | finance.yahoo.comEvoke launches audience intelligence offering to unlock full commercial potential of life sciences brandsAugust 10, 2023 | msn.comEvoke Pharma GAAP EPS of -$0.56 beats by $0.17, revenue of $1.13M beats by $0.03MAugust 10, 2023 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports Second Quarter 2023 Financial ResultsSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 10, 2023 | finance.yahoo.comEvoke Pharma Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comMayo's Aidan O'Shea and fiancée Kristin celebrate engagement in exotic locationAugust 7, 2023 | finance.yahoo.comEvoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) MeetingAugust 3, 2023 | forbes.comThe Psychology Of Color: 5 Ways You Can Use Color To Build Brand IdentityJuly 29, 2023 | msn.comFeeling like a winner: Mayo's Aidan O'Shea pops the questionJuly 25, 2023 | finance.yahoo.comEvoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual MeetingJuly 15, 2023 | msn.com10 surprising facts you never knew about SudocremJuly 5, 2023 | finance.yahoo.comEV00.BE - Evoke Pharma IncJune 14, 2023 | finance.yahoo.comEvoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its TreatmentMay 17, 2023 | marketwatch.com2023, Gastroenterology Market Growth Status and Outlook- 2030May 16, 2023 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports First Quarter 2023 Financial ResultsMay 15, 2023 | benzinga.comEvoke Pharma Reports First Quarter 2023 Financial ResultsMay 15, 2023 | msn.comEvoke Pharma GAAP EPS of -$0.67 misses by $0.09, revenue of $0.81M misses by $0.19MMay 9, 2023 | finance.yahoo.comReal-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare ResourcesMay 4, 2023 | finance.yahoo.comEvoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023April 20, 2023 | finance.yahoo.comUnited States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTIApril 9, 2023 | marketwatch.com8-K: Evoke Pharma IncApril 6, 2023 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related PatentSee More Headlines Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EVOK Company Calendar Last Earnings8/10/2023Today9/27/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,220,000.00 Net Margins-222.13% Pretax Margin-222.13% Return on Equity-258.20% Return on Assets-71.61% Debt Debt-to-Equity Ratio9.29 Current Ratio4.29 Quick Ratio4.04 Sales & Book Value Annual Sales$2.51 million Price / Sales1.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book0.85Miscellaneous Outstanding Shares3,340,000Free Float2,949,000Market Cap$3.46 million OptionableNot Optionable Beta0.37 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. David A. Gonyer R.Ph. (Age 59)Co-Founder, CEO & Director Comp: $806.53kMr. Matthew J. D'Onofrio MBA (Age 53)Co-Founder, Pres & COO Comp: $557.11kDr. Marilyn R. Carlson (Age 75)Chief Medical Officer Comp: $518.14kMr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)Key CompetitorsAptevo TherapeuticsNASDAQ:APVODermata TherapeuticsNASDAQ:DRMAABVC BioPharmaNASDAQ:ABVCPanbela TherapeuticsNASDAQ:PBLARedHill BiopharmaNASDAQ:RDHLView All Competitors EVOK Stock - Frequently Asked Questions How have EVOK shares performed in 2023? Evoke Pharma's stock was trading at $2.68 at the start of the year. Since then, EVOK shares have decreased by 61.4% and is now trading at $1.0350. View the best growth stocks for 2023 here. Are investors shorting Evoke Pharma? Evoke Pharma saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 17,700 shares, an increase of 391.7% from the August 31st total of 3,600 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is currently 1.4 days. Approximately 0.5% of the shares of the company are sold short. View Evoke Pharma's Short Interest. When is Evoke Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our EVOK earnings forecast. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) issued its quarterly earnings data on Thursday, August, 10th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.13 million for the quarter. Evoke Pharma had a negative net margin of 222.13% and a negative trailing twelve-month return on equity of 258.20%. When did Evoke Pharma's stock split? Shares of Evoke Pharma reverse split on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY). What is Evoke Pharma's stock symbol? Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK." How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evoke Pharma's stock price today? One share of EVOK stock can currently be purchased for approximately $1.04. How much money does Evoke Pharma make? Evoke Pharma (NASDAQ:EVOK) has a market capitalization of $3.46 million and generates $2.51 million in revenue each year. The specialty pharmaceutical company earns $-8,220,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. How can I contact Evoke Pharma? Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The official website for the company is www.evokepharma.com. The specialty pharmaceutical company can be reached via phone at (858) 345-1494 or via email at tbui@theruthgroup.com. This page (NASDAQ:EVOK) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.